Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Correction to: Immunotherapy Utilizing the Combination of Natural Killer- and Antibody Dependent Cellular Cytotoxicity (ADCC)-Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition.

Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW.

J Immunother Cancer. 2019 Sep 2;7(1):234. doi: 10.1186/s40425-019-0715-9.

2.

Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.

Lee KL, Benz SC, Hicks KC, Nguyen A, Gameiro SR, Palena C, Sanborn JZ, Su Z, Ordentlich P, Rohlin L, Lee JH, Rabizadeh S, Soon-Shiong P, Niazi K, Schlom J, Hamilton DH.

Cancer Immunol Res. 2019 Aug;7(8):1359-1370. doi: 10.1158/2326-6066.CIR-18-0620. Epub 2019 Jul 10.

PMID:
31292145
3.

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.

Knudson KM, Hicks KC, Alter S, Schlom J, Gameiro SR.

J Immunother Cancer. 2019 Mar 21;7(1):82. doi: 10.1186/s40425-019-0551-y.

4.

The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex.

Jochems C, Tritsch SR, Knudson KM, Gameiro SR, Rumfield CS, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J.

Oncoimmunology. 2018 Nov 27;8(2):e1532764. doi: 10.1080/2162402X.2018.1532764. eCollection 2019.

5.

Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.

Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW.

J Immunother Cancer. 2018 Nov 29;6(1):133. doi: 10.1186/s40425-018-0445-4. Erratum in: J Immunother Cancer. 2019 Sep 2;7(1):234.

6.

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.

Hicks KC, Fantini M, Donahue RN, Schwab A, Knudson KM, Tritsch SR, Jochems C, Clavijo PE, Allen CT, Hodge JW, Tsang KY, Schlom J, Gameiro SR.

Oncoimmunology. 2018 Jul 30;7(11):e1466018. doi: 10.1080/2162402X.2018.1466018. eCollection 2018.

7.

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.

Friedman J, Morisada M, Sun L, Moore EC, Padget M, Hodge JW, Schlom J, Gameiro SR, Allen CT.

J Immunother Cancer. 2018 Jun 21;6(1):59. doi: 10.1186/s40425-018-0374-2.

8.

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.

Knudson KM, Hicks KC, Luo X, Chen JQ, Schlom J, Gameiro SR.

Oncoimmunology. 2018 Feb 14;7(5):e1426519. doi: 10.1080/2162402X.2018.1426519. eCollection 2018. Erratum in: Oncoimmunology. 2019 Feb 27;8(5):e1584435.

10.

Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing.

Gameiro SR, Malamas AS, Bernstein MB, Tsang KY, Vassantachart A, Sahoo N, Tailor R, Pidikiti R, Guha CP, Hahn SM, Krishnan S, Hodge JW.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):120-30. doi: 10.1016/j.ijrobp.2016.02.022. Epub 2016 Feb 13.

11.

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.

Kwilas AR, Ardiani A, Gameiro SR, Richards J, Hall AB, Hodge JW.

Oncotarget. 2016 Apr 26;7(17):23498-511. doi: 10.18632/oncotarget.8274.

12.

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.

Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW.

Oncotarget. 2016 Feb 16;7(7):7390-402. doi: 10.18632/oncotarget.7180.

13.

Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.

Kwilas AR, Gameiro SR, Kim PS, Malamas AS, Hodge JW.

Oncoimmunology. 2015 Mar 2;4(6):e1009303. eCollection 2015 Jun.

14.

Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities.

Garnett-Benson C, Hodge JW, Gameiro SR.

Semin Radiat Oncol. 2015 Jan;25(1):46-53. doi: 10.1016/j.semradonc.2014.07.002. Review.

15.
16.

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens.

Gameiro SR, Ardiani A, Kwilas A, Hodge JW.

Oncoimmunology. 2014 Apr 29;3:e28643. eCollection 2014.

17.

Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.

Aryankalayil MJ, Makinde AY, Gameiro SR, Hodge JW, Rivera-Solis PP, Palayoor ST, Ahmed MM, Coleman CN.

Radiat Res. 2014 Aug;182(2):139-48. doi: 10.1667/RR13731.1. Epub 2014 Jul 8.

18.

Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions.

Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C.

Cancer Biother Radiopharm. 2014 May;29(4):153-61. doi: 10.1089/cbr.2013.1578. Epub 2014 Apr 2.

19.

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.

Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW.

Br J Cancer. 2014 Mar 18;110(6):1472-80. doi: 10.1038/bjc.2014.79. Epub 2014 Feb 20.

20.

Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J, Hodge JW.

Cancer Res. 2014 Apr 1;74(7):1945-57. doi: 10.1158/0008-5472.CAN-13-2045. Epub 2014 Feb 11.

21.

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

Hodge JW, Kwilas A, Ardiani A, Gameiro SR.

Oncoimmunology. 2013 Dec 1;2(12):e26937. Epub 2013 Nov 6.

22.

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.

Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW.

Oncotarget. 2014 Jan 30;5(2):403-16.

23.

Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.

Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW.

PLoS One. 2013 Jul 24;8(7):e70417. doi: 10.1371/journal.pone.0070417. Print 2013.

24.

Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise.

Gameiro SR, Jammeh ML, Hodge JW.

Expert Rev Vaccines. 2013 Jun;12(6):617-29. doi: 10.1586/erv.13.40. Review.

PMID:
23750792
25.

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR.

Int J Cancer. 2013 Aug 1;133(3):624-36. doi: 10.1002/ijc.28070. Epub 2013 Mar 16.

26.

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR.

Semin Oncol. 2012 Jun;39(3):323-39. doi: 10.1053/j.seminoncol.2012.02.006. Review.

27.

Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.

Gameiro SR, Caballero JA, Hodge JW.

Cancer Biother Radiopharm. 2012 Feb;27(1):23-35. doi: 10.1089/cbr.2012.1203. Epub 2012 Feb 8.

28.

Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

Hodge JW, Sharp HJ, Gameiro SR.

Cancer Biother Radiopharm. 2012 Feb;27(1):12-22. doi: 10.1089/cbr.2012.1202. Epub 2012 Jan 27.

29.

Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.

Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW.

Cancer Immunol Immunother. 2011 Sep;60(9):1227-42. doi: 10.1007/s00262-011-1020-8. Epub 2011 May 5.

30.

Vaccines as monotherapy and in combination therapy for prostate cancer.

Rotow J, Gameiro SR, Madan RA, Gulley JL, Schlom J, Hodge JW.

Clin Transl Sci. 2010 Jun;3(3):116-22. doi: 10.1111/j.1752-8062.2010.00186.x.

Supplemental Content

Loading ...
Support Center